Long Position on RTRX @ $20.20 on 8/4/2017 (Momentum)

Retrophin, Inc. (RTRX) is a biopharmaceutical company.

The firm focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.

Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

The company's product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc (RE-034), a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

Shares have formed a bullish "cup and handle" ahead of its earnings report today. The formation is supported by the stock's 30-day moving average shown in brown. Estimates call for a loss of 23 cents per share. Higher share prices are expected for this stock.

52-Weeks Trading Range: $15.55 - $24.57

Entry Point: $20.20

Stop Loss: $19.00

Target Price: $22.30 

Updates

8/15/2017 9:35:45 AM

RTRX closed at $22.30

Position closed on 8/15/2017 at price of $22.30 with a 10.40% gain in 11 days.

Back to Portfolio